Pharma doesn't want more questions than answers, so you can't do development on a shoestring or cut corners...BrainStorm Cell Therapeutics Inc., of New York, said it has signed a $250,000 common stock purchase agreement with an individual private investor

BrainStorm Cell Therapeutics Inc., of New York, said the Israeli Ministry of Health fast-tracked the firm's Phase I/II amyotrophic lateral sclerosis safety study to a Phase IIa dose-escalating trial, which significantly expedites the clinical development program...Cerulean Pharma Inc., of Cambridge, Mass., said CRLX101 achieved the predefined gating criterion for advancement into the second stage of a Phase II trial in advanced ovarian cancer...The complete clinical study report for the interim

Cerulean Pharma Inc., of Cambridge, Mass., said it dosed the first patient in a Phase II study of lead candidate CRLX101 in advanced gastric cancer...Dipexium Pharmaceuticals LLC, of New York, said it reached an agreement with the FDA on a special protocol assessment for an upcoming Phase III study testing Locilex (pexiganan acetate cream 1 percent), an antibiotic peptide formulated as a topical cream, in mild infections of diabetic foot ulcers...TG Therapeutics Inc., of New York, said the FDA cleared

As a small biotech with one foot in infectious disease and the other in neurology while having one hand in commercial products and the other in clinical development, "we have a unique strategy, and so far it's working well," Musunuri said...New York investment fund Platinum-Montaur Life Sciences LLC exercised Series W warrants to purchase 6 million shares of common stock in Navidea Biopharmaceuticals Inc., of Dublin, Ohio

EyeGate Pharma Inc., of Waltham, Mass., said it enrolled the last patient in a 200-subject pivotal Phase III study of EGP-437 (dexamethasone phosphate ophthalmic solution) in patients with anterior uveitis...Transparency Life Sciences LLC, of New York, said the FDA cleared an investigational new drug application for lisinopril in multiple sclerosis

Data also indicated rapid onset of activity, with clinical activity reported for 16 of 19 responders occurring within the first two cycles of treatment...OncoSec plans to use the proceeds to fund clinical trials and research and development and for other corporate purposes...The company plans to use the proceeds to fund research and development, clinical trials and for other corporate purposes.

CellAct Pharma GmbH, of Dortmund, Germany, said its topoisomerase inhibitor CAP7...Intercept Pharmaceuticals Inc., of New York, completed patient enrollment in the FLINT Phase IIb trial of obeticholic acid (OCA) for adult nonalcoholic steatohepatitis

At least a year shy of the next milestone payment from partner Astellas Pharma Inc., Ambit Biosciences Inc...Funds will be used for working capital and general corporate purposes, including the funding of its ongoing clinical trials...The net proceeds will be used for working capital and general corporate purposes, including the continued conduct of the Abili-T clinical study, Opexa's recently initiated Phase IIb trial of personalized T-cell therapy Tcelna in patients with secondary progressive

TransTech Pharma Inc., of High Point, N.C., said data from a 399-patient study testing TTP488, a small-molecule drug targeting the receptor for advanced glycation endproducts, demonstrated evidence of slowing cognitive decline over 18 months in patients with mild to moderate Alzheimer's disease...The study was sponsored by New York-based Pfizer Inc

The clinical relevance of neratinib as a 'pan-HER' family inhibitor and it being irreversible is yet to be proven," the paper said...Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities.

Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, reported that the reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with Eliquis (apixaban) compared to warfarin in the ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation

Berg Pharma LLC, of Boston, began a Phase I trial of compound 31543 for chemotherapy-induced alopecia...BrainStorm Cell Therapeutics Inc., of New York, said it completed a planned interim safety review of its Phase I/II amyotrophic lateral sclerosis (ALS) trial, indicating that autologous transplantation of the firm's cell therapy was well tolerated, appears to be safe for use and did not present any undue risks to the study participants...Cerulean Pharma Inc., of Cambridge, Mass., said it dosed the

Results were presented at the Multinational Association of Supportive Care in Cancer Conference in New York...Isotechnika Pharma Inc., of Edmonton, Alberta, said 3SBio Inc., of Shenyang, China, received approval in China to begin a Phase III trial of voclosporin

Bristol-Myers Squibb Co., of New York, formed a strategic partnership with Emory University in Atlanta to conduct clinical trials involving the pharma's investigational compounds...Forest Laboratories Inc., of New York, said it was notified that entities affiliated with Carl C. Icahn intend to nominate four individuals to Forest's 10-member board for election at the company's 2012 annual meeting

Data were presented at the American Society of Hypertension meeting in New York...1 percent of patients with moderately to severely active ulcerative colitis who received gut-selective monoclonal antibody vedolizumab experienced clinical response vs. 25.5 percent in the placebo group (p < 0.0001

Syndax Pharmaceuticals Inc., of Waltham, Mass., said Phase II data published in the Journal of Clinical Oncology confirmed preclinical findings and demonstrated an improved overall survival in a subset of non-small-cell lung cancer (NSCLC) patients with tumors expressing elevated levels of E-cadherin treated with the company's HDAC inhibitor entinostat in combination with EGFR inhibitor Tarceva (erlotinib, Astellas Pharma Inc. and Roche AG...Ventrus Biosciences Inc., of New York, said it completed

Assuming the final clinical study report supports the preliminary findings, RedHill said it will consider filing for U.S...Synergy Pharmaceuticals Inc., of New York, reached the halfway mark for patient enrollment in its ongoing plecanatide Phase II/III trial in chronic idiopathic constipation patients